ZEISS Research Microscopy Solutions’ strengths in automated, high-resolution imaging and 3D image analysis are strongly related to strategic investment.
To enhance the use of 3D microtissues in research and medication development, ZEISS is investing in the life science start-up InSphero. The latest fundraising round for InSphero AG, a leader in 3D spheroid and cell-based assays for pharmaceutical drug discovery and safety assessment, saw the company raise an eight-figure sum. InSphero will use the money to market its cryo-preservation technology in order to promote further expansion and scalability. The fundraising round includes ZEISS Ventures as well as internal and foreign investors.
InSphero’s all-inclusive preclinical medication safety and efficacy testing solutions are built on 3D microtissues, phenotypic representations of a tissue or organ’s tiniest functional unit. These drug development and testing platforms include scalable 3D technology, 3D human tissue models that have undergone ISO quality control, media that has been tuned for 3D, and specialized assay services and support. Partners in drug discovery have direct access to the breadth and depth of InSphero’s expertise in creating and using 3D models for oncology, metabolic disorders, and liver toxicity.
“The FDA Modernization Act provides new benefits to the industry for sophisticated 3D in-vitro models. This Act raises non-animal drug development approaches to the same standard as animal testing. With its highly industrialized platform solution, InSphero has a unique position to take advantage of this market potential, according to Gerrit Schulte, Head of ZEISS Ventures.
The FDA Modernization Act’s widespread usage of 3D microtissues necessitates rapid, effective, automation-compatible 3D models, according to Dr. Jan Lichtenberg, CEO and Co-Founder of InSphero. Our innovative array of cryopreserved ARCTis 3D Microtissue provides a storable, constantly available option for effective and enlightening chemical testing. The largest 3D microtissue biobank in the world is on its way to being established by us.
“Our strategy initiative, Life Science Industrialization, is ideally matched with the strategic investment we made in InSphero. By utilizing ZEISS expertise, we will position our technology as a critical enabler for widely used and standardized workflows in applied life sciences and healthcare. To give customers end-to-end workflows, we anticipate close cooperation with InSphero, says Dr. Michael Albiez, Head of ZEISS Research Microscopy Solutions.
Click on the following link, Metrologically Speaking to read more such news about the Metrology Industry.
